期刊
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
卷 35, 期 3, 页码 556-564出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2010.06.007
关键词
Parkinson's disease; L-DOPA; Anxiety; Depression; Affect; Animal models; Serotonin; Dopamine; Norepinephrine
资金
- NINDS [NIH NS059600]
- Center for Development and Behavioral Neuroscience at Binghamton University
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059600] Funding Source: NIH RePORTER
Though the most recognizable symptoms of Parkinson's disease (PD) are motor-related, many patients also suffer from debilitating affective symptoms that deleteriously influence quality of life. Dopamine (DA) loss is likely involved in the onset of depression and anxiety in PD. However, these symptoms are not reliably improved by DA replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA). In fact, preclinical and clinical evidence suggests that L-DOPA treatment may worsen affect. Though the neurobiological mechanisms remain unclear, recent research contends that L-DOPA further perturbs the function of the norepinephrine and serotonin systems, already affected by PD pathology, which have been intimately linked to the development and expression of anxiety and depression. As such, this review provides an overview of the clinical characteristics of affective disorders in PD, examines the utility of animal models for the study of anxiety and depression in PD, and finally, discusses potential mechanisms by which DA loss and subsequent L-DOPA therapy influence monoamine function and concomitant affective symptoms. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据